SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.26 CNY | +1.13% |
|
+11.13% | -4.29% |
| Apr. 23 | Salubris Pharmaceuticals' Q1 Profit Falls 5% Despite 23% Rise in Operating Income | MT |
| Apr. 23 | Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 20,858 | 29,138 | 30,220 | 36,225 | 35,644 | 34,116 | - | - |
| Enterprise Value (EV) 1 | 20,089 | 28,673 | 27,054 | 33,743 | 34,373 | 30,919 | 30,939 | 34,116 |
| P/E ratio | 29.3 x | 472 x | 54.6 x | 56.6 x | 62.8 x | 52.4 x | 42.2 x | 38.4 x |
| Yield | 2.51% | - | 1.46% | 1.52% | 1.53% | 1.7% | 1.39% | 2.05% |
| Capitalization / Revenue | 4.67 x | 10.6 x | 9.88 x | 10.4 x | 10.6 x | 8.69 x | 7.2 x | 6.15 x |
| EV / Revenue | 4.49 x | 10.5 x | 8.85 x | 9.69 x | 10.2 x | 7.88 x | 6.53 x | 6.15 x |
| EV / EBITDA | 18.4 x | 83.6 x | 30 x | 31.7 x | 33.9 x | 28.7 x | 25.5 x | 22.5 x |
| EV / FCF | - | 39.1 x | - | 90.6 x | - | 53.4 x | 42 x | 44.9 x |
| FCF Yield | - | 2.56% | - | 1.1% | - | 1.87% | 2.38% | 2.23% |
| Price to Book | 3.21 x | 5.38 x | 3.79 x | 4.61 x | 4.54 x | 4.31 x | 3.84 x | 4.06 x |
| Nbr of stocks (in thousands) | 1,046,016 | 1,028,513 | 1,106,137 | 1,102,746 | 1,091,359 | 1,091,359 | - | - |
| Reference price 2 | 19.94 | 28.33 | 27.32 | 32.85 | 32.66 | 31.26 | 31.26 | 31.26 |
| Announcement Date | 2/28/20 | 3/29/21 | 3/28/22 | 3/28/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,470 | 2,739 | 3,058 | 3,482 | 3,365 | 3,924 | 4,740 | 5,544 |
| EBITDA 1 | 1,093 | 343.2 | 900.4 | 1,064 | 1,013 | 1,079 | 1,211 | 1,518 |
| EBIT 1 | 846.1 | 79.22 | 586.2 | 727.4 | 656 | 790.9 | 936.1 | 1,090 |
| Operating Margin | 18.93% | 2.89% | 19.17% | 20.89% | 19.49% | 20.15% | 19.75% | 19.65% |
| Earnings before Tax (EBT) 1 | 851.3 | 56.74 | 599.8 | 713.7 | 641.8 | 790.3 | 965.7 | 1,076 |
| Net income 1 | 715.2 | 60.86 | 533.7 | 636.9 | 580.1 | 674.4 | 826.3 | 911 |
| Net margin | 16% | 2.22% | 17.45% | 18.29% | 17.24% | 17.19% | 17.43% | 16.43% |
| EPS 2 | 0.6800 | 0.0600 | 0.5000 | 0.5800 | 0.5200 | 0.5967 | 0.7400 | 0.8150 |
| Free Cash Flow 1 | - | 732.8 | - | 372.4 | - | 578.6 | 736.1 | 760.4 |
| FCF margin | - | 26.76% | - | 10.7% | - | 14.74% | 15.53% | 13.72% |
| FCF Conversion (EBITDA) | - | 213.53% | - | 34.99% | - | 53.62% | 60.77% | 50.1% |
| FCF Conversion (Net income) | - | 1,203.91% | - | 58.47% | - | 85.78% | 89.09% | 83.47% |
| Dividend per Share 2 | 0.5000 | - | 0.4000 | 0.5000 | 0.5000 | 0.5300 | 0.4350 | 0.6400 |
| Announcement Date | 2/28/20 | 3/29/21 | 3/28/22 | 3/28/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 1 | 0.1200 | 0.2200 | 0.0900 | 0.1800 | 0.0900 | 0.1900 | 0.1100 | 0.1300 | 0.0900 | 0.1800 | 0.1200 | 0.1500 | 0.1700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 4/18/22 | 8/9/22 | 10/24/22 | 3/28/23 | 4/18/23 | 8/24/23 | 10/30/23 | 3/25/24 | 4/22/24 | - | - | - |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 769 | 465 | 3,166 | 2,482 | 1,271 | 3,197 | 3,177 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 733 | - | 372 | - | 579 | 736 | 760 |
| ROE (net income / shareholders' equity) | 11.1% | 1.03% | 7.6% | 8.13% | 7.35% | 8.15% | 9.25% | 10.6% |
| ROA (Net income/ Total Assets) | 9.15% | 0.83% | 6.6% | 6.71% | - | 6.95% | 8.3% | 8.65% |
| Assets 1 | 7,819 | 7,324 | 8,081 | 9,500 | - | 9,704 | 9,955 | 10,532 |
| Book Value Per Share 2 | 6.200 | 5.270 | 7.210 | 7.120 | 7.190 | 7.260 | 8.140 | 7.710 |
| Cash Flow per Share 2 | 1.440 | 1.310 | 1.110 | 0.8700 | 0.7500 | 0.8100 | 0.8400 | 1.060 |
| Capex 1 | - | 642 | 481 | 598 | 670 | 481 | 501 | 502 |
| Capex / Sales | - | 23.43% | 15.72% | 17.18% | 19.92% | 12.26% | 10.58% | 9.06% |
| Announcement Date | 2/28/20 | 3/29/21 | 3/28/22 | 3/28/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
31.26
CNY
Average target price
37
CNY
Spread / Average Target
+18.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.29% | 4.71B | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 002294 Stock
- Financials Shenzhen Salubris Pharmaceuticals Co., Ltd.
